Rena J. Eudy-Byrne, Ph.D.

Senior Scientist I

Rena joined Metrum in November 2015 after completing her Ph.D. in Biomedical Engineering at the University of Connecticut. Her dissertation work included extending a systems pharmacology model of bone and osteoporosis to be relevant for the development new therapies. Part of this work included linking simulated changes in bone mineral density to a hazard model of fracture in a Bayesian framework in order to predict the probability of fracture in osteoporosis patients. Analysis tools for establishing a priori identifiability of target-mediated drug disposition and other indirect response-type models were also part of this larger work. Rena brings 5 years of industry experience to the team, including work in preclinical development in metabolic systems and neuroscience and using systems pharmacology models to inform clinical decisions.

Recent publications by this scientist

Pharmacometric Dose Optimization of Buprenorphine in Neonatal Opioid Withdrawal Syndrome

June 3, 2021

Eudy-Byrne, R., Zane, N., Adeniyi-Jones, S.C., Gastonguay, M.R., Ruiz-Garcia, A., Kushal, G. and Kraft, W.K. (2021). Clinical and Translational Science. Accepted Author Manuscript. https://doi.org/10.1111/cts.13074

View More

A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes

April 16, 2021

Johnston CK, Eudy-Byrne RJ, Elmokadem A, Nock V, Marquard J, Soleymanlou N, Riggs MM, Liesenfeld K-H. Pharmaceutics. 2021; 13(4):485. https://doi.org/10.3390/pharmaceutics13040485

View More

Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity.

November 13, 2020

Kang J, Eudy-Byrne RJ, Mondick J, Knebel W, Jayadeva G, Liesenfeld KH. Br J Clin Pharmacol. 2020 Nov;86(11):2274-2285. doi: 10.1111/bcp.14330.

View More